Find Drugs for Cardiology/Vascular Diseases in Phase III Clinical Development in UNITED KINGDOM

Lead Product(s): Ticagrelor,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

BRILINTA reduced the risk of the composite of stroke and death after an acute ischemic stroke or transient ischemic attack.

Lead Product(s): Dapagliflozin

Therapeutic Area: Cardiology/Vascular Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 06, 2020

Details:

The sNDA was based on results from the landmark Phase III DAPA-HF trial, which showed FARXIGA reduced the incidence of the composite outcome of CV death or the worsening of HF versus placebo.